RITTER PHARMACEUTICALS INC RTTR Income Statement

Ritter pharmaceuticals inc (RTTR)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Sep'14	Jun'14
Operating costs and expenses:
Research and development
2,553	6,126	12,123	14,546	14,985	12,259	6,932	4,388	3,291	2,874	8,302	9,735	11,841	13,292	7,787	6,944	4,111	2,260	1,642	143	0	0	0
Patent costs
-	-	-	-	-	-	-	-	-	-	-	-	317	272	283	232	213	243	0	0	0	-	-
Patent costs
101	146	173	211	189	204	0	0	0	-	0	0	-	-	-	-	-	-	-	-	-	0	0
General and administrative
5,626	4,570	5,089	5,111	5,452	5,425	5,367	5,275	4,732	4,777	4,715	4,755	4,818	4,881	5,078	5,542	6,337	6,404	5,026	3,823	0	0	0
Total operating costs and expenses
8,282	10,844	17,386	19,869	20,627	17,889	12,545	9,896	8,259	7,902	13,266	14,790	16,977	18,446	13,149	12,718	10,662	8,908	6,858	4,136	0	0	0
Operating loss
-8,282	-10,844	-17,386	-19,869	-20,627	-17,889	-12,545	-9,896	-8,259	-7,902	-13,266	-14,790	-16,977	-18,446	-13,149	-12,718	-10,662	-8,908	-6,858	-4,136	0	0	0
Other income:
Other expense
-	-	-	-	-	-	-	-	-	-	-	-	-	1	64	73	73	79	0	0	0	-	0
Interest income (expense), net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-
Interest income
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Interest income
-	-	179	183	-	126	86	73	58	40	28	37	48	60	68	73	59	40	0	0	0	-	-
Settlement of accounts payable
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total other income
1,187	711	1,073	1,077	1,065	1,020	85	72	56	38	28	37	48	62	132	147	133	120	27	0	0	0	-
Net loss
-7,094	-10,133	-16,313	-18,792	-19,561	-16,868	-12,460	-9,824	-8,203	-7,863	-13,237	-14,752	-16,929	-18,384	-13,016	-12,570	-10,529	-8,787	-6,831	-4,142	0	0	0
Other comprehensive gain:
Unrealized gain on debt securities
-	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Comprehensive loss
-7,095	-10,132	-16,313	-18,792	-19,561	-16,869	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-7,094	-10,133	-16,313	-18,792	-19,561	-16,868	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cumulative preferred stock dividends
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	327	474	622	0	0	0
Accretion of discount of Series C preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-63	0	0	0	-	-
Net loss applicable to common stockholders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-9,178	-7,369	-4,827	0	0	0
Net loss per common share - basic and diluted
-0.05	0.06	-0.23	-0.31	-0.58	-1.68	-0.86	-0.71	-0.41	-1.96	-0.14	-1.41	-1.44	-0.79	-0.41	-0.48	-0.36	4.84	-0.40	-4.18	-3.37	-0.92	-1.18
Weighted average common shares outstanding - basic and diluted
34,910	11,674	9,507	9,042	8,055	5,835	5,373	5,064	4,944	-8,453	14,756	1,395	1,161	10,219	8,585	8,584	8,583	2,977	7,792	551	465	451	456